Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates

Circulation

Volumn 98, Issue 22, 1998, Pages 2461-2469

  Harker, Laurence A ^a   Marzec, Ulla M ^a   Kelly, Andrew B ^a   Chronos, Nicolas R F ^a   Birgitta Sundell, I ^a   Hanson, Stephen R ^a   Herbert, J M ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

Author keywords

Aspirin; Clopidogrel; Stents; Thrombus

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRIN;

ANIMAL EXPERIMENT; ARTERY THROMBOSIS; ARTICLE; BABOON; BLOOD VESSEL GRAFT; DRUG EFFICACY; DRUG INHIBITION; ENDARTERECTOMY; FIBRIN FORMATION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; STENT; THROMBOGENESIS; VASCULAR DISEASE;

EID: 0032403010     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.22.2461     Document Type: Article

References (35)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
2. Chesebro JH, Fuster V. The therapeutic challenge of plaque rupture: value of biochemical markers. J Am Coll Cardiol. 1987;10:1005-1009.
3. Fuster V, Jang I-K. Role of platelet-inhibitor agents in coronary artery disease. In: Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia. Pa: WB Saunders; 1994:3-22.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 1994;308:159-168.
5. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I: acetylation of a particulate fraction protein. J Clin Invest. 1975;56:624-632.
6. Hass WK, Easton JD, Adams HP. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321:501-507.
7. Gent M, Blakely JA, Easton JD. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-1220.
8. Janzon L, Bergqvist D, Boberg J. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990;227:301-308.
9. Becquemin J-P, Etude de la Ticlopidine apres Pontage Femoro-Poplite, Association Universitaire de Recherche en Chirurgie. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med. 1997;337:1726-1731.
10. Mills DCB, Puri R, Hu C-J, Minniti C, Grana G, Freedman MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb. 1992;12:430-436.
11. Mills DCB. ADP receptors on platelets. Thromb Haemost. 1996;76: 835-856.
12. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost. 1996;76: 939-943.
13. Van Belle E, McFadden EP, Lablanche JM, Bauters C, Harmon M, Bertrand ME. Two-pronged antiplatelet therapy with aspirin and ticlopidine without systemic anticoagulation: an alternative therapeutic rategy after bailout stent implantation. Coron Artery Dis. 1995;6: 341-345.
14. Morice MC, Zemour G, Benveniste E, Biron Y, Bourdonnec C, Faivre R, Majadet J, Gaspard P, Glatt B, Joly P, Labrunie P, Lienhart Y, Marco J, Petiteau P, Rover T, Valeix B. Intracoronary stenting without coumadin: one month results of a French multicenter study. Cathet Cardiovasc Diagn. 1995;35:1-7.
15. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stems. N Engl J Med. 1996;334:1084-1089.
16. . Goods CM, al-Shaibi KF, Liu MW, Yadav JS, Mathur A, Jain SP, Dean LS, Iyer SS, Parks JM, Roubin GS. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol. 1996;78:1042-1044.
17. Herbert JM, Frechel D, Vallee E. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev. 1993;11:180-198.
18. Herbert JM, Tissinier A, Defreyn G, Maffrand JP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation following arterial injury in rabbits. Arterioscler Thromb. 1993;13:1171-1179.
19. Savi P, Combalbert J, Graich C, Rouchon MC, Maffrand JP, Berger Y, Herben JM. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994;72:313-317.
20. 3H]-2-methyl-thioADP to rat platelets: effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 1994;269:772-777.
21. Coukell AJ, Markham A. Clopidogrel. Drugs. 1997;54:745-750.
22. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaernia. Lancet. 1996;348: 1329-1339.
23. Harker LA, Hanson SR. Experimental strategies for assessing anti-thrombotic benefits and hemorrhagic risks of novel antithrombotic agents. In: Sasahara A, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York, NY: Marcel Dekker: 1997:29-48.
24. 111indium-labeled platelets in baboons. Blood. 1986;68:386-393.
25. Harker LA, Hanson SR, Kirkman TR. Experimental arterial thrombembolism in baboons: mechanism, quantitation, and pharmacologic prevention. J Clin Invest. 1979;64:559-569.
26. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic amithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethylketone. Proc Natl Acad Sci U S A. 1988;85: 3184-3188.
27. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood. 1991;77:1006-1012.
28. Harker LA, Kelly AB, Hanson SR. Experimental arterial thrombosis in non-human primates. Circulation. 1991;83(suppl IV):IV-41-IV-55.
29. Cadroy Y, Hanson SR, Kelly AB, Marzec UM, Evatt BL, Kunicki TJ, Montgomery RR, Harker LA. Relative antithrombotic effects of monoclonal antibodies targeting different platelet slycoprotein-adhesive molecule interactions in non-human primates. Blood. 1994;83: 3218-3224.
30. Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries: flow cytometric detection. Arterioscler Thromb. 1992;12: 1475-1487.
31. Hansen SR, Pareti FI, Ruggeri ZM, Kunicki TJ, Montgomery RR, Zimmerman TS, Harker LA. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest. 1988;81:149-158.
32. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular Thrombosis: Thrombocardiology. Philadelphia. Pa: Lippincott-Raven: 1998:3-22.
33. Gachet C, Stierle A, Cazenave JP, Ohlrnann P, Lanza F, Bouloux C, Maffrand JP. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol. 1990;40:229-238.
34. 1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost. 1991;65:186-190.
35. Harker LA. Platelets and vascular thrombosis. N Engl J Med. 1994;330: 1006-1007.